Mor Moskovitz

1.9k total citations
62 papers, 823 citations indexed

About

Mor Moskovitz is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Mor Moskovitz has authored 62 papers receiving a total of 823 indexed citations (citations by other indexed papers that have themselves been cited), including 37 papers in Oncology, 34 papers in Pulmonary and Respiratory Medicine and 10 papers in Cancer Research. Recurrent topics in Mor Moskovitz's work include Lung Cancer Treatments and Mutations (30 papers), Lung Cancer Diagnosis and Treatment (13 papers) and Cancer Immunotherapy and Biomarkers (11 papers). Mor Moskovitz is often cited by papers focused on Lung Cancer Treatments and Mutations (30 papers), Lung Cancer Diagnosis and Treatment (13 papers) and Cancer Immunotherapy and Biomarkers (11 papers). Mor Moskovitz collaborates with scholars based in Israel, United States and Canada. Mor Moskovitz's co-authors include Mira Wollner, Elizabeth Dudnik, Jair Bar, Alona Zer, Tzippy Shochat, Nir Peled, Georgeta Fried, Damien Urban, Ofer Rotem and Hovav Nechushtan and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Gastroenterology.

In The Last Decade

Mor Moskovitz

59 papers receiving 795 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mor Moskovitz Israel 15 453 406 138 108 92 62 823
Damien Urban Israel 19 758 1.7× 492 1.2× 194 1.4× 173 1.6× 115 1.3× 59 1.2k
Ioannis Gkiozos Greece 16 376 0.8× 348 0.9× 213 1.5× 46 0.4× 31 0.3× 63 887
San‐Chi Chen Taiwan 16 260 0.6× 167 0.4× 128 0.9× 118 1.1× 123 1.3× 53 785
Nynke Zwart Netherlands 16 194 0.4× 138 0.3× 191 1.4× 159 1.5× 75 0.8× 25 648
Luca Cantini Italy 15 330 0.7× 351 0.9× 101 0.7× 152 1.4× 49 0.5× 76 797
Vincenzo Pagliarulo Italy 17 181 0.4× 514 1.3× 290 2.1× 379 3.5× 22 0.2× 75 1.1k
Halil Kavgacı Türkiye 14 174 0.4× 106 0.3× 132 1.0× 96 0.9× 68 0.7× 55 623
Tarık Salman Türkiye 16 314 0.7× 107 0.3× 84 0.6× 109 1.0× 39 0.4× 67 585
Pengwei Ren China 18 219 0.5× 232 0.6× 336 2.4× 87 0.8× 47 0.5× 48 909
Virginia Martínez-Marín Spain 13 210 0.5× 197 0.5× 67 0.5× 91 0.8× 42 0.5× 29 570

Countries citing papers authored by Mor Moskovitz

Since Specialization
Citations

This map shows the geographic impact of Mor Moskovitz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mor Moskovitz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mor Moskovitz more than expected).

Fields of papers citing papers by Mor Moskovitz

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mor Moskovitz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mor Moskovitz. The network helps show where Mor Moskovitz may publish in the future.

Co-authorship network of co-authors of Mor Moskovitz

This figure shows the co-authorship network connecting the top 25 collaborators of Mor Moskovitz. A scholar is included among the top collaborators of Mor Moskovitz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mor Moskovitz. Mor Moskovitz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Shalata, Walid, Jair Bar, Mor Moskovitz, et al.. (2025). Lurbinectedin for extensive stage − small cell lung cancer (ES-SCLC): real world response patterns and survival outcomes. Lung Cancer. 205. 108598–108598. 1 indexed citations
2.
Moskovitz, Mor, et al.. (2025). Targeting HER2 in lung cancers: Evolving treatment landscape and drug development strategies. Cancer. 131(S1). e35780–e35780.
3.
4.
Tschernichovsky, Roi, Shlomit Yust‐Katz, Ofer Rotem, et al.. (2024). Converging survival trends in non-small cell lung cancer patients with and without brain metastasis receiving state-of-the-art treatment. Journal of Neuro-Oncology. 166(3). 461–469. 1 indexed citations
5.
Moskovitz, Mor, et al.. (2024). Seeing the Trees From the Forest: Challenges in Subgroup Analysis-Based Guidelines in Oncology. Oncology Reviews. 18. 1355256–1355256.
6.
Moskovitz, Mor, Sivan Shamai, Barliz Waissengrin, et al.. (2023). P2.07-09 Stage 3 NSCLC Patients Progressing After Concurrent Chemo-Radiotherapy and Durvalumab- is There a Role for Another IO?. Journal of Thoracic Oncology. 18(11). S327–S327. 1 indexed citations
7.
Shamai, Sivan, Barliz Waissengrin, Damien Urban, et al.. (2022). 41P Progression after chemo-IO and durvalumab in stage III non-small cell lung cancer (NSCLC): What should be the next line? Real-world study. Annals of Oncology. 33. S51–S51. 2 indexed citations
8.
Shachar, Shlomit Strulov, Gil Bar‐Sela, Avivit Peer, et al.. (2022). The association between geriatric assessment, muscle measures, and treatment-related toxicity in older adults with cancer: An Israeli prospective study. Journal of Geriatric Oncology. 13(8). 1203–1207. 7 indexed citations
9.
Moskovitz, Mor, Damien Urban, Hovav Nechushtan, et al.. (2021). dNLR-Based Score Predicting Overall Survival Benefit for The Addition of Platinum-Based Chemotherapy to Pembrolizumab in Advanced NSCLC With PD-L1 Tumor Proportion Score ≥50%. Clinical Lung Cancer. 23(2). 122–134. 17 indexed citations
10.
Schaefer, Eric, D. Ross Camidge, Kiyotaka Yoh, et al.. (2021). A phase 1b, open-label, single-arm study of cofetuzumab pelidotin (a PTK7-targeting antibody-drug conjugate) in patients with PTK7-expressing, recurrent non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology. 39(15_suppl). TPS3142–TPS3142. 5 indexed citations
11.
Dudnik, Elizabeth, Abed Agbarya, Arnold Cyjon, et al.. (2020). Clinical activity of brigatinib in ROS1-rearranged non-small cell lung cancer. Clinical & Translational Oncology. 22(12). 2303–2311. 14 indexed citations
12.
Dudnik, Elizabeth, Jair Bar, Mor Moskovitz, et al.. (2019). P2.06-14 BAP1 Mutant Malignant Pleural Mesothelioma (MPM): Outcomes with Chemotherapy, ICPi and PARPi. Journal of Thoracic Oncology. 14(10). S760–S760. 1 indexed citations
13.
Dudnik, Elizabeth, Mor Moskovitz, Abed Agbarya, et al.. (2019). OA11.06 Alternative Nivolumab (N) Duration and Scheduling in Advanced Non-Small Cell Lung Cancer (aNSCLC): Real-Life Data. Journal of Thoracic Oncology. 14(10). S235–S236. 6 indexed citations
14.
15.
Cabanero, Michael, Mor Moskovitz, Jonathan M. Weiss, et al.. (2018). P3.03-29 The Prognostic Effect of Tumor Mutation Burden and Smoking History in Resected EGFR Mutant Non-Small Cell Lung Cancer. Journal of Thoracic Oncology. 13(10). S921–S921. 1 indexed citations
16.
Zer, Alona, Mor Moskovitz, David Hwang, et al.. (2017). OA21.02 ALK-Rearranged Non-Small Cell Lung Cancer is Associated with a High Rate of Venous Thromboembolism. Journal of Thoracic Oncology. 12(1). S326–S327. 1 indexed citations
17.
Zer, Alona, Mor Moskovitz, David Hwang, et al.. (2016). ALK-Rearranged Non–Small-Cell Lung Cancer Is Associated With a High Rate of Venous Thromboembolism. Clinical Lung Cancer. 18(2). 156–161. 72 indexed citations
18.
Fried, Georgeta & Mor Moskovitz. (2014). Treatment decisions in estrogen receptor-positive early breast cancer patients with intermediate oncotype DX recurrence score results. SpringerPlus. 3(1). 71–71. 18 indexed citations
19.
Shai, Ayelet, et al.. (2013). Conservative Management for an Entero-Adnexal Fistula at Initial Presentation of Advanced Ovarian Carcinoma. Current Oncology. 20(1). 44–47. 3 indexed citations
20.
Moskovitz, Mor, et al.. (1992). Large hiatal hernias, anemia, and linear gastric erosion: studies of etiology and medical therapy.. PubMed. 87(5). 622–6. 39 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Damien Urban Breakdown of academic impact, for papers by Ioannis Gkiozos Breakdown of academic impact, for papers by San‐Chi Chen Breakdown of academic impact, for papers by Nynke Zwart Breakdown of academic impact, for papers by Luca Cantini Breakdown of academic impact, for papers by Vincenzo Pagliarulo Breakdown of academic impact, for papers by Halil Kavgacı Breakdown of academic impact, for papers by Tarık Salman Breakdown of academic impact, for papers by Pengwei Ren Breakdown of academic impact, for papers by Virginia Martínez-Marín
Rankless by CCL
2026